| 1. |
- Kanai, M, et al.
(author)
-
- 2023
-
swepub:Mat__t
|
|
| 2. |
- Niemi, MEK, et al.
(author)
-
- 2021
-
swepub:Mat__t
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Hayes, A., et al.
(author)
-
A European multicentre evaluation of detection and typing methods for human enteroviruses and parechoviruses using RNA transcripts
- 2020
-
In: Journal of Medical Virology. - : Wiley. - 0146-6615 .- 1096-9071. ; 92:8, s. 1065-1074
-
Journal article (peer-reviewed)abstract
- Polymerase chain reaction (PCR) detection has become the gold standard for diagnosis and typing of enterovirus (EV) and human parechovirus (HPeV) infections. Its effectiveness depends critically on using the appropriate sample types and high assay sensitivity as viral loads in cerebrospinal fluid samples from meningitis and sepsis clinical presentation can be extremely low. This study evaluated the sensitivity and specificity of currently used commercial and in-house diagnostic and typing assays. Accurately quantified RNA transcript controls were distributed to 27 diagnostic and 12 reference laboratories in 17 European countries for blinded testing. Transcripts represented the four human EV species (EV-A71, echovirus 30, coxsackie A virus 21, and EV-D68), HPeV3, and specificity controls. Reported results from 48 in-house and 15 commercial assays showed 98% detection frequencies of high copy (1000 RNA copies/5 µL) transcripts. In-house assays showed significantly greater detection frequencies of the low copy (10 copies/5 µL) EV and HPeV transcripts (81% and 86%, respectively) compared with commercial assays (56%, 50%; P = 7 × 10−5). EV-specific PCRs showed low cross-reactivity with human rhinovirus C (3 of 42 tests) and infrequent positivity in the negative control (2 of 63 tests). Most or all high copy EV and HPeV controls were successfully typed (88%, 100%) by reference laboratories, but showed reduced effectiveness for low copy controls (41%, 67%). Stabilized RNA transcripts provide an effective, logistically simple and inexpensive reagent for evaluation of diagnostic assay performance. The study provides reassurance of the performance of the many in-house assay formats used across Europe. However, it identified often substantially reduced sensitivities of commercial assays often used as point-of-care tests.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Franco, L, et al.
(author)
-
Dengue in Africa : sustained and silent circulation of multiple serotypes and genotypes, detected in travelers from 2010 to 2014
- 2015
-
In: Tropical medicine & international health. - : Wiley-Blackwell. - 1360-2276 .- 1365-3156. ; 20:Suppl. 1, s. 107-108
-
Journal article (other academic/artistic)abstract
- Introduction: Dengue is caused by 4 different related viruses, DENV 1 to 4, transmitted to humans via Aedes mosquitoes. The disease is endemic in more than 100 countries. In Africa, the estimated dengue burden is 15 million of clinical cases and about 48 millions of inapparent infections. However, dengue remains largely unrecognized in Africa. Due to the lack of laboratory confirmation, a febrile syndrome is frequently misdiagnosed as malarial infection. The circulation of different dengue serotypes is also poorly documented. However, some information is provided by reports of dengue infections in travellers returning from Africa. In the present study we attempt the identification of dengue serotypes and genotypes circulating in Africa from 2010 to 2014 detected in travellers returning to Europe.Methods: We collected samples from viraemic travellers returning from Africa who attended TropNet clinics in Europé from 2010 to 2014. Sequences of the Envelope gene were used to identify the serotype and genotype.Results: During the study period we identified 3 DENV serotypes circulating in Africa. DENV 1 strains were detected in East Africa in 2010 (Eritrea) and in 2012 (Kenia), whereas in Central Africa in 2013(Angola and DRC). Strains from East Africa were grouped within Asian genotype, close to virus isolated in previous years in Djibouti and Kenia; we found American /African genotype in Central Africa. Both genotypes have circulated in West Africa for many years. DENV 2 strains were detected in West Africa (Senegal) and in East Africa (Tanzania) in 2014. Dengue 2 from Tanzania belongs to cosmopolitan genotype, but form a distinct clade different from the old African group. However, DENV 2 from Senegal surprisingly fell into genotype America /Asia. To our knowledge this is the first time identified in Africa. Finally, DENV 3 was detected in 2010 in Mali and Burkina Faso and again in Burkina Faso in 2013. All DENV 3 belong to genotype III and form a cluster with the African strains identified since 2008.Conclusion: DENV 1 of both genotypes was identified previously in Africa indicating endemic transmission as well as with DENV 3. Meanwhile, a new DENV 2 appeared in Tanzania, introduced from South East Asia, and in Senegal from the Americas. These results confirm silent and sustained circulation of dengue in Africa and show the usefulness of travelers for sentinel surveillance to unmask the dengue problem in Africa.Disclosure: Nothing to disclose.
|
|
